BATM Advanced Communications Ld First commercial agreement for Ador (9134Y)
January 07 2020 - 2:00AM
UK Regulatory
TIDMBVC
RNS Number : 9134Y
BATM Advanced Communications Ld
07 January 2020
LEI: 213800FLQUB9J289RU66
7 January 2020
BATM Advanced Communications Limited
("BATM" or "the Group")
First Commercial Agreement for Ador Diagnostics
Molecular diagnostics subsidiary receives order for meningitis
testing
BATM (LSE: BVC; TASE: BVC), a leading provider of real-time
technologies for networking solutions and medical laboratory
systems, announces that Ador Diagnostics ("Ador"), the Group's
subsidiary focused on the development and marketing of unique
in-vitro molecular diagnostics solutions, has received its first
commercial order from the leading Italian distributor of molecular
biology and genomics products. Under the agreement, Ador will
deliver the new NATlab reader and cartridges for the identification
of meningitis in the second half of 2020.
Ador's NATlab molecular biology solution provides rapid
sample-to-answer diagnosis of bacterial, viral or fungal
infections, within approximately 15-90 minutes, using DNA sampling.
The unique system is modular, compact and mobile, and is designed
to be used at the point-of-care as well as in hospital labs. The
Group believes that NATlab will allow medical practitioners to
provide far quicker and more efficient treatment.
This first commercial order for the new system follows extensive
lab testing and the award of over 40 global patents, including in
Europe and the US, with more pending. The first models of NATlab
are expected to go into final trials in leading hospitals in the
first half of this year, with the initial system having been
already delivered this month.
Dr Zvi Marom, Chief Executive Officer of BATM, said: "We are
delighted that Ador has received the first commercial order for the
NATlab system, which is an important milestone. Meningitis is a
leading infectious cause of childhood death - and speed of
identification and treatment is vital. We are proud that our rapid
sample-to-answer solution will help medical practitioners to
quickly and efficiently diagnose the specific infection and
administer the required treatment.
"We believe NATlab will transform the infectious disease
diagnostics market and we have already received extremely positive
feedback and significant interest from several leading medical
institutions that are testing the solution. Ador is also working
alongside prominent academic and research institutions, including
in the UK, to develop more panels for the identification of further
diseases. We look forward to reporting on Ador's progress."
Enquiries:
BATM Advanced Communications
Dr Zvi Marom, Chief Executive Officer +972 9866 2525
Moti Nagar, Chief Financial Officer
Shore Capital
Mark Percy, Anita Ghanekar, James Thomas (Corporate Advisory)
Henry Willcocks (Corporate Broking) +44 20 7408 4050
Luther Pendragon
Harry Chathli, Claire Norbury, Rachel So +44 20 7618 9100
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRFFFFILVIRIII
(END) Dow Jones Newswires
January 07, 2020 02:00 ET (07:00 GMT)
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Batm Advanced Communicat... (LSE:BVC)
Historical Stock Chart
From Apr 2023 to Apr 2024